JP2002506036A - 疾患を処置するにおける新規ヌクレオシドアナログおよびその使用 - Google Patents

疾患を処置するにおける新規ヌクレオシドアナログおよびその使用

Info

Publication number
JP2002506036A
JP2002506036A JP2000535350A JP2000535350A JP2002506036A JP 2002506036 A JP2002506036 A JP 2002506036A JP 2000535350 A JP2000535350 A JP 2000535350A JP 2000535350 A JP2000535350 A JP 2000535350A JP 2002506036 A JP2002506036 A JP 2002506036A
Authority
JP
Japan
Prior art keywords
compound
fluoro
oriented
deoxyuridine
evaporated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000535350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002506036A5 (fr
Inventor
アレクサンダー エル． ウェイス，
キルパサビー ピュレンティラン，
アネット エム． ジェロ，
Original Assignee
リピテック インターナショナル， インコーポレイテッド
ユニサーチ リミテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/038,647 external-priority patent/US5939402A/en
Application filed by リピテック インターナショナル， インコーポレイテッド, ユニサーチ リミテツド filed Critical リピテック インターナショナル， インコーポレイテッド
Publication of JP2002506036A publication Critical patent/JP2002506036A/ja
Publication of JP2002506036A5 publication Critical patent/JP2002506036A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000535350A 1998-03-11 1999-03-11 疾患を処置するにおける新規ヌクレオシドアナログおよびその使用 Pending JP2002506036A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/038,647 1998-03-11
US09/038,647 US5939402A (en) 1995-09-21 1998-03-11 Nucleoside analogs and uses against parasitic infection
US09/219,947 1998-12-23
US09/219,947 US6242428B1 (en) 1995-09-21 1998-12-23 Nucleoside analogs and uses in treating Plasmodium falciparum infection
US09/220,307 US6207649B1 (en) 1995-09-21 1998-12-23 Nucleoside analogs and uses in treating disease
US09/220,307 1998-12-23
PCT/US1999/005360 WO1999045935A1 (fr) 1998-03-11 1999-03-11 Nouveaux analogues de nucleosides et leurs utilisations dans le traitement de maladies

Publications (2)

Publication Number Publication Date
JP2002506036A true JP2002506036A (ja) 2002-02-26
JP2002506036A5 JP2002506036A5 (fr) 2006-04-27

Family

ID=27365434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000535350A Pending JP2002506036A (ja) 1998-03-11 1999-03-11 疾患を処置するにおける新規ヌクレオシドアナログおよびその使用

Country Status (5)

Country Link
EP (1) EP1069903A1 (fr)
JP (1) JP2002506036A (fr)
AU (1) AU3080899A (fr)
CA (1) CA2322494A1 (fr)
WO (1) WO1999045935A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516641A (ja) * 2003-02-03 2006-07-06 シーブイ・セラピューティクス・インコーポレイテッド アデノシン受容体の完全アゴニストおよび部分アゴニスト

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4294870B2 (ja) * 1998-08-10 2009-07-15 インデニックス ファーマシューティカルズ リミティド Ｂ型肝炎の治療のためのβ−Ｌ−２’−デオキシ−ヌクレオシド
AU2004201286B2 (en) * 1998-08-10 2007-06-21 Centre National De La Recherche Scientifique (Cnrs) Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
AU2007216721B2 (en) * 1998-08-10 2011-05-19 Centre National De La Recherche Scientifique Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP1352910A1 (fr) * 2002-04-10 2003-10-15 Grünenthal GmbH Nouveaux derives d'analogues de nitrobenzylthioinosine
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
GB0400290D0 (en) * 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
WO2015181624A2 (fr) * 2014-05-28 2015-12-03 Idenix Pharmaceuticals, Inc Dérivés de nucléosides pour le traitement du cancer
EP3149017B1 (fr) * 2014-05-28 2019-12-11 Idenix Pharmaceuticals LLC Dérivés de nucléosides pour le traitement du cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5672594A (en) * 1994-10-24 1997-09-30 Genencor International, Inc. L-erythrosyl nucleosides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516641A (ja) * 2003-02-03 2006-07-06 シーブイ・セラピューティクス・インコーポレイテッド アデノシン受容体の完全アゴニストおよび部分アゴニスト

Also Published As

Publication number Publication date
WO1999045935A1 (fr) 1999-09-16
AU3080899A (en) 1999-09-27
EP1069903A1 (fr) 2001-01-24
CA2322494A1 (fr) 1999-09-16

Similar Documents

Publication Publication Date Title
US6242428B1 (en) Nucleoside analogs and uses in treating Plasmodium falciparum infection
US10968248B2 (en) Trinucleotide mRNA cap analogs
EP3233882B1 (fr) Dinucléotides cycliques fluorés pour l'induction de la cytokine
US5614505A (en) Method of treating cancer with homo-oligonuleotides of 5-FU 5'-monophosphate
US4963662A (en) Fluorinated nucleosides and method for treating retrovirus infections therewith
EP0980377B1 (fr) Analogues de nucleosides de pyrimidine antiviraux
EP1280813B1 (fr) Analogues de nucleoside pyrimidique a action antivirale
US20040132684A1 (en) Polymeric nucleoside prodrugs
JP2021522862A (ja) ７’−５’−アルファ−アノマー二環式糖ヌクレオシドを含むオリゴヌクレオチドコンジュゲート
KR20100072230A (ko) 아자시티딘 유사체 및 이의 용도
US11919922B2 (en) Bicyclic nucleosides and oligomers prepared therefrom
JP2002506036A (ja) 疾患を処置するにおける新規ヌクレオシドアナログおよびその使用
JP2947580B2 (ja) ２′，５′―オリゴアデニレート誘導体の治療的使用
US6342485B1 (en) Synergistic compositions useful as anti-tumor agents
US5153180A (en) Fluorinated nucleosides and process for treating retrovirus infections therewith
WO2004083155A2 (fr) Derives d'esters lipidiques nucleotidiques
Van Camp Decitabine (Dacogen): A DNA methyltransferace inhibitor for cancer
Soodin The attempted synthesis of 2'-[2-amino-3 (p-methoxyphenyl) propanamido]-2'-deoxy-N6N6-dimethyladenosine, an isomer of the antibiotic and antitumour drug Puromycin

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100224